Abstract:Background and objective Nowadays, comprehensive treatment, including surgery, chemotherapy and radiotherapy is advocated for stage III non-small cell lung cancer (NSCLC). However, many researchers have questioned the effectiveness of surgery. The aim of this study is to evaluate the effect of surgery for stage III NSCLC. Methods Between March 2002 and October 2012, 310 cases that have completed followed-up data with stage III NSCLC were received in the Peking Union Medical College Hospital. They were divided into surgical and non-surgical groups according to whether received surgery when diagnosed. In TNM staging, stage III NSCLC includes stage IIIa and IIIb, and stage IIIa NSCLC can be grouped into stage T4N0/T3-4N1M0 and T1-3N2M0 according to different N stages. Analyzed the enumeration data by Chi-Square test. Kaplan-Meier survival method was used to calculate the overall survival (OS) and progression-free survival (PFS), and to draw the survival curves. A P value less than 0.05 was evaluated as statistically significant. Results Three hundred and ten stage III NSCLC patients include surgical group 189 cases and non-surgical group 121 cases. One hundred and eighty-eight stage IIIa NSCLC patients include surgical group 152 cases and non-surgical group 36 cases. In stage IIIa, stage T4N0/T3-4N1M0 had 57 patients with 44 surgical and 13 non-surgical patients, and stage T1-3N2M0 had 131 patients with 108 surgical and 23 non-surgical patients. Thirty-seven out of 121 stage IIIb NSCLC patients received surgery. They had 22 stage T4N2M0 cases and 15 stage T1-4N3M0 cases. The patient whose performance status was 0 and staging was stage IIIa was more inclined to undergo surgery. For stage IIIa NSCLC patients, the median OS of surgical and non-surgical groups were 38.9 and 21.8 months, and the median PFS of them were 19.2 and 11.9 months respectively. The difference of OS between the two groups was significant (P=0.041), but the PFS of them had no significant difference (P=0.209). For stage T4N0/T3-4N1M0 which belongs to stage IIIa, the median OS of surgical and non-surgical groups were 48.7 and 20.1 months, and the median PFS of them were 14.6 and 10.5 months respectively. There were no significant differences of OS and PFS between the two groups (P>0.05). For stage T1-3N2M0 which also belongs to stage IIIa, the median OS of surgical and non-surgical groups were 38.9 and 30.8 months, and the median PFS of them were 19.8 and 12.7 months respectively. There were also no significant differences of OS and PFS between the two groups (P>0.05). The maximum diameter of tumor and auxillary chemotherapy had significant influences on OS and PFS of stage IIIa-N2 NSCLC patients, while the histology of tumor only influenced the OS of them (P<0.05). Conclusion The patient whose performance status is 0 and staging is stage IIIa is more inclined to undergo surgery. Surgery can prolong OS of patients with stage IIIa, especially for stage T4N0/T3-4N1M0. However, it has no benefit on PFS. The maximum diameter of tumor and auxillary chemotherapy have significant influences on OS and PFS of stage IIIa-N2 NSCLC patients, while the histology of tumor only influence the OS of them.

Retrospective study on surgery and post-operative adjuvant treatment in stage Ⅲa non-small cell lung cancer

Value of Surgery for Stage IIIa Non-small Cell Lung Cancer

[Survival Analysis of 121 Stage N2-IIIa Non-small Cell Lung Cancer Patients Treated with Surgery].

Surgical Intervention Improves Survival for Metastatic Non-Small Cell Lung Cancer Patients.

Comparison of Surgeries Plus Perioperative and Postoperative Chemotherapies in Chinese Pn2 Patients with Non-Small Cell Lung Cancer: A Real-World Observational Study.

[Surgical Treatment for Stage III N2 Non-Small Cell Lung Cancer].

Survival Analysis of Non-Small Cell Lung Cancer Patients with Adjuvant Chemotherapy.

Role of Surgery in a Case-Control Study of Patients with Clinical Stage IIIA Small Cell Lung Cancer

Comparative Analysis of Different Therapies for Stage I-III Non-small Cell Lung Cancer After Complete Resection

The prognosis of completed resectable ⅢA non-small cell lung cancer and the suggestion of the treatment strategy

Effects of Postoperative Adjuvant Radiotherapy on Stage IIIA-N2 Non-Small Cell Lung Cancer and Prognostic Analysis.

[Prognostic Analysis of Curative Surgery for Stage IIIA-N2 Non-Small Cell Lung Cancer].

A prospective randomized study of adjuvant chemotherapy in completely resected stage ⅢA-N2 non-small cell lung cancer

Adjuvant Chemotherapy Following Radical Surgery for Non-Small-cell Lung Cancer: a Randomized Study on 70 Patients.

Survival Analysis of 220 Patients with Completely Resected Stage-Ii Non-Small Cell Lung Cancer

P3-245: Survival Improvement During Two Decades in Stage IIIA NSCLC Patients from Single Institution

Therapeutic Evaluation of Postoperative Radiotherapy for Patients with Completely Resected Stage IIIa(N_2) Non-Small Cell Lung Cancer

Survival and Progostic Factors in Resected ⅢA-N2 Non-small Cell Lung Cancer : A Study of 288 Cases

Clinical outcomes of surgery after induction treatment in patients with pathologically proven N2-positive stage III non-small cell lung cancer.

Surgical therapy after concomitant chemo-radiotherapy for stage Ⅲ non-small cell lung cancer

Subsequent surgical treatment or maintenance immunotherapy in stage III lung cancer patients achieving a favorable response following neoadjuvant immunotherapy: A matched retrospective cohort study from the surgical perspective